<DOC>
	<DOCNO>NCT00377091</DOCNO>
	<brief_summary>This study compare two blood thinner accept standard care , fondaparinux unfractionated heparin ( UFH ) . These drug use prevent growth exist blood clot formation additional blood clot patient pulmonary embolism ( blood clot lung ) begin take warfarin ( another standard care blood thinner ) . Patients invited participate diagnose pulmonary embolism , require anticoagulation therapy ( treatment blood thinner ) , currently hospitalize . The purpose study determine patient treat fondaparinux short hospital stay low cost treatment hospital similar patient receive different standard care UFH . Fondaparinux already approve FDA use patient pulmonary embolism , inpatient outpatient care , long treatment begin warfarin hospitalize . It therefore experimental treatment . The study conduct determine FDA approve treatment best practice hospital treatment pulmonary embolism . The study also examine safety effectiveness fondaparinux local use .</brief_summary>
	<brief_title>Is Using Fondaparinux ( Blood Thinner ) Treat Lung Clot Cheaper Than Traditional Therapy</brief_title>
	<detailed_description>Research Question This study conduct determine treatment pulmonary embolism ( PE ) fondaparinux decrease length stay hospital cost therapy maintain safety efficacy , compare unfractionated heparin ( UFH ) . Primary research question : Determine PE treatment utilize fondaparinux reduce inpatient length stay ( LOS ) cost hospital care St. Mary 's Duluth Clinic Health System ( SMDC ) , compare match group patient treat UFH standard care , time period . Secondary research question : Determine bleed recurrent thrombosis rate similar fondaparinux cohort UFH match control group . Specific Aims 1 . Enroll 30 St. Mary 's Medical Center ( SMMC , affiliate SMDC ) patient treatment cohort , utilize fondaparinux primary immediate antithrombin therapy , warfarin titrate therapeutic effect . 2 . Retrospectively identify matched control group 30 PE patient , treat UFH standard care , period time . 3 . Determine LOS cost inpatient care standardize scale treatment cohort control group . 4 . Perform retrospective review patient ' medical record 3 month initial pulmonary embolism , determine rate : 4a . repeat venous thromboembolism event ( VTE ) 4b . bleed event</detailed_description>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>1 . Patients 18 year age old present acute symptomatic pulmonary embolism require antithrombotic therapy 2 . Diagnostic confirmation base follow criterion 1. intraluminal filling defect spiral compute tomography ( CT ) pulmonary angiography 2. highprobability ventilationperfusion lung scan , nondiagnostic lung scan documentation deepvein thrombosis , either compression ultrasonography venography . 3 . Primary outpatient MD record SMDC MD patient outpatient MD event occur . 4 . For match control ( UFH ) cohort : unfractionated heparin utilized initial antithrombotic therapy . ( LMWH use allow initially fondaparinux arm . ) Patient willingness fondaparinux injection administer outpatient , family member , caregiver . 1 . Patients ineligible study receive therapeutic dos UFH LMWH oral anticoagulant 24 hour ; 2 . Patient required thrombolysis , embolectomy , vena cava filter ; 3 . Anticoagulant therapy contraindicate example , active bleeding thrombocytopenia ( platelet count 100,000 per cubic millimeter ) . 4 . Patients ineligible estimate creatinine clearance &lt; 30 mL/min . 5 . Uncontrolled hypertension ( systolic blood pressure great 180 mm Hg diastolic blood pressure great 110 mm Hg ) ; 6 . Pregnancy 7 . Physician estimate life expectancy less three month . 8 . Patients weigh &gt; 150 kg 9 . Indwelling epidural catheter 10 . Inability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>pulmonary embolism</keyword>
	<keyword>venous thromboembolism</keyword>
	<keyword>pharmacoeconomic</keyword>
	<keyword>heparin</keyword>
	<keyword>unfractionated heparin</keyword>
	<keyword>fondaparinux</keyword>
	<keyword>length stay</keyword>
	<keyword>cost</keyword>
	<keyword>bleeding</keyword>
	<keyword>thrombosis</keyword>
</DOC>